EANS-Adhoc: Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Research & Development

11.02.2010

» Initial results from a first-in-man Phase I study indicate safety
and immunogenicity of the Streptococcus pneumoniae vaccine candidate

Vienna (Austria), February 11, 2010 - Intercell AG (VSE: "ICLL")
today announced results from a Phase I clinical trial investigating
the company's vaccine candidate for the prevention of infections by
the bacterium Streptococcus pneumoniae. Intercell's investigational
prophylactic vaccine candidate (IC47) is a recombinant subunit
vaccine consisting of three highly conserved proteins of
Streptococcus pneumoniae.

In the first-in-man trial, 32 healthy adults were vaccinated with
Intercell's investigational vaccine. Two antigen dosages, with and
without addition of aluminum hydroxide, were applied in four
different study groups.

The initial analysis of the data has indicated a good safety and
tolerability of the vaccine candidate, which was confirmed by a Data
Safety Monitoring Board. The vaccine was immunogenic, and antigen
dose-dependent induction of antibodies was confirmed for all three
proteins of the vaccine.

"We are pleased that we have been able to generate first-in-man data
for a further vaccine candidate based on antigens discovered through
our Antigen Identification Program (AIP®). Subject to clearance with
the authorities and our partners, we next intend to initiate clinical
development in two target populations - children and the elderly,"
stated Thomas Lingelbach, Intercell's Chief Operating Officer.

About Streptococcus pneumoniae infections

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial
infection in both industrialized and developing countries. In
particular, young children and the elderly represent high-risk
populations for developing pneumococcal infections. Annually,
according to the World Health Organization, the bacterium kills up to
one million children under the age of five years worldwide. It
accounts for many bacterial Meningitis cases in adults, is the most
common cause of Pneumonia, and also causes Bacteremia, Meningitis,
and Otitis media in young children.

About Intercell's Streptococcus pneumoniae vaccine

The Company´s vaccine candidate is a recombinant subunit vaccine
consisting of three conserved surface proteins from Streptococcus
pneumoniae. Two of these proteins were discovered using Intercell's
proprietary Antigen Identification Program (AIP®), while the third
was in-licensed from the U.S. Centers for Disease Control and
Prevention (CDC). The development of Intercell's vaccine to prevent
pneumococcal disease is supported by PATH, an international global
health non-profit organization.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market